A client is seeking information about the varicella vaccine (Varivax) What should the nurse inform the client about the vaccine?

Choice B rationale:

The symptoms described in the scenario, such as fever, headache, malaise, anorexia, pharyngitis, and the progression of a generalized pruritic rash from macules to papules to vesicles to pustules to crusts, are indicative of varicella-zoster virus (VZV) infection, commonly known as chickenpox. Otitis media (choice B) can be a complication of chickenpox, especially in children.

Choice A rationale:

Chronic kidney disease (choice A) is not a common complication of chickenpox. It is more commonly associated with conditions like diabetes and hypertension.

Choice C rationale:

Rheumatoid arthritis (choice C) is an autoimmune condition and is not a known complication of chickenpox.

Choice D rationale:

Type 2 diabetes (choice D) is not a common complication of chickenpox. Diabetes can increase the risk of infection, but it is not directly related to chickenpox.

Choice A rationale:

Varivax is not administered as a single dose during adulthood. The vaccine is given as two doses, usually separated by 4 to 8 weeks, to ensure adequate protection.

Choice B rationale:

Varivax can reduce the risk of developing shingles, especially in individuals who had chickenpox and received the vaccine. While it may not completely prevent shingles, it can lessen its severity.

Choice C rationale:

This is the correct response. Varivax is a live attenuated vaccine, which means it contains weakened forms of the varicella-zoster virus that causes chickenpox. It stimulates the immune system to produce a protective response without causing the disease.

Choice D rationale:

Varivax is not recommended only for healthcare workers. It is recommended for certain groups, including children, adolescents, and adults who have not had chickenpox or received the vaccine. Healthcare workers might be among the targeted groups due to their increased risk of exposure, but it is not limited to them.